CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027

Summary

Report Description

Global CAR-T cell therapy market stood at USD1709.00 million in 2021 and is expected to grow at a CAGR of 64.66% during the forecast period. This can be attributed to the increasing prevalence of different types of cancer globally. Additionally, the approval of new CAR-T cell therapies such as ABECMA (idecabtagene vicleucel) increased the demand for CAR-T cell therapies for the treatment of cancer. This, in turn, fueled the market growth of CAR-T cell therapy globally. Additionally, the increase in the number of cell therapy clinical studies, especially in the United States and China, also supports market growth over the next few years. Also, flourishing pharmaceutical research expenditure by both the governments and private industries across the different regions is expected to foster market growth during the forecast period.

Focus on Personalized Medicine Driving Market Growth

Personalized medicine is the beginning to overcome all the limitations of traditional medicine. Increasing personalized medicines allows healthcare providers to shift the emphasis in medicine from reaction to prevention. Personalized medicines have the potential to improve health care while also lowering costs. It enables an earlier diagnosis, risk management, and better treatment for the patient. Growing public knowledge and acceptance of customized medicine has fueled demand for cell-based therapies like CAR-T cell therapy to treat a variety of chronic illnesses.

Growing Prevalence of Cancer Supporting Market Growth

During the projected period, the rising prevalence of various types of cancer, particularly various forms of Lymphoma and Leukemia, is expected to boost the growth of the global CAR-T cell therapy market. According to Globocan statistics, there were roughly 19,292,789 new cancer cases registered in 2020. Breast, lung, colorectum, prostate, and stomach cancer were the most common kinds of cancer. Similarly, Non-Hodgkin Lymphoma was rated 12th, while Leukemia was placed 14th, with 544,352 and 474,519 instances reported for each kind, respectively. CAR-T cell therapies are used to treat different types of cancer which supports the market growth. For instance, YESCARTA is a CAR-T cell therapy, which is used to treat large B-cell lymphoma or follicular lymphoma.

Increase in Cell Therapy Clinical Studies Aids Market Growth

The growing awareness related to cell-based therapies and their benefits in treating various types of diseases and disorders has increased the research & development activities related to cell-based therapies, which leads to an increase in the number of clinical trials worldwide. Additionally, many people are eager to get themselves enrolled in clinical studies especially related to CAR-T cell therapy, thereby fueling the market growth through 2027. For instance, 1304 ongoing or upcoming CAR-related trials were registered at ClinicalTrials.gov as of December 22, 2020. Out of which, a total of 433 trials (56%) were from China and 288 (37%) from the United States.

Increasing Demand for Organic Pesticides to support Market Growth

Organic pesticide market growth is primarily driven by rising consumer awareness of organic products and foods. Synthetic pesticides used in agricultural production are detrimental to humans and the environment. Organic pesticides are chemical-free, environmentally beneficial, and create fewer toxic residues, making them essential for organic farming. The demand for organic pesticides is also influenced by increased disposable income, environmental concerns, and comparable prices.

Faster Approvals of CAR-T Cell Therapies Supports the Market Growth

The first CAR-T cell therapy was approved on August 30, 2017, by the brand name of Kymirah and the second was approved in the same year by the name of Yescarta. Till December 2021, there are five approved CAR-T cell therapies globally. The most recent approved CAR-T cell therapy is Abecma by Bluebird Bio and BMS and is approved in the year 2021. This number is continuously increasing as many CAR-T cell therapies are on the edge of approval by the US-FDA. For instance, in September 2021, China’s National Medical Products Administration (NMPA) has approved its CAR-T cell immunotherapy of JW Therapeutics’ Relmacabtagene autoleucel injection by the brand name of relma-cel.

Click here to download the sample

Market Segmentation

The global CAR-T cell therapy market is segmented based on product type, tumor type, indication, treatment type, targeted antigen, end user, company, and regional distribution. On the basis of product type, the market can be split into YESCARTA (axicabtagene ciloleucel), KYMRIAH (tisagenlecleucel), TECARTUS (brexucabtagene autoleucel), BREYANZI (lisocabtagene maraleucel), ABECMA (idecabtagene Vicleucel), and Others. Based on tumor type, the market is divided into Hematological Malignancies and Solid Tumors.

Based on indication, the market can be divided into Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Others. In terms of treatment type, the market divided into Single Treatment and Combination Treatment. Based on targeted antigen, the market is segmented into CD 19, BCMA, and Others. In terms of end user, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others.

Company Profiles

Gilead Sciences Inc, Novartis International AG, Bristol Myers Squibb Company, AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc, Merck & Co. Inc., Intellia Therapeutics Inc., Poseida Therapeutics Inc, Johnson & Johnson, Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc, Sangamo Therapeutics, Inc, and among others are among the major market players in the regional platform that lead the market growth of the Global CAR-T Cell therapy market.

Attribute	Details
Market size value in 2021	USD1709.00 Million
Revenue Forecast in 2027	USD33153.30 Million
United States Market Size in 2021	USD784.31 Million
Growth Rate	64.66%
Base Year	2021
Historical Years	2017 – 2020
Estimated Year	2022
Forecast Period	2023 – 2027
Quantitative Units	Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027
Report Coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments Covered	· Product Type · Tumor Type · Indication · Treatment type · Targeted Antigen · End User
Regional Scope	North America, Europe, Asia Pacific, South America, Middle East & Africa
Country Covered	United States, Canada, Mexico, Germany, France, Switzerland, United Kingdom, Italy, Spain, China, Japan, India, Australia, South Korea, Brazil, Argentina, Colombia, Israel, South Africa, Saudi Arabia, UAE
Key Companies Profiled	Gilead Sciences Inc, Novartis International AG, Bristol Myers Squibb Company, AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc, Merck & Co. Inc., Intellia Therapeutics Inc., Poseida Therapeutics Inc, Johnson & Johnson, Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc, Sangamo Therapeutics, Inc
Customization Scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/pdf format on special request)

Report Scope:

In this report, Global CAR-T Cell Therapy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global CAR-T Cell Therapy, By Product Type:

Yescarta (Axicabtagene Ciloleucel)
Kymriah (Tisagenlecleucel)
Tecartus (Brexucabtagene Autoleucel)
Breyanzi (Lisocabtagene Maraleucel)
Abecma (Idecabtagene Vicleucel)
Others

Global CAR-T Cell Therapy Market, By Tumor Type:

Hematological Malignancies
Solid Tumors

Global CAR-T Cell Therapy Market, By Indication:

Diffused Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Follicular Lymphoma (FL)
Mantle Cell Lymphoma (MCL)
Others

Global CAR-T Cell Therapy Market, By Treatment Type:

Single Treatment
Combination Treatment

Global CAR-T Cell Therapy Market, By Targeted Antigen

CD19
BCMA
Others

Global CAR-T Cell Therapy Market, By End User:

Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Others

Global CAR-T Cell Therapy Market, By Region:

North America
Europe
Asia-Pacific
South America
Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global CAR-T cell therapy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of content

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global CAR-T Cell Therapy Market

5. Voice of Customers

5.1. Brand Awareness

5.2. Unmet Need and Challenges

5.3. Factors Driving the CAR-T Cell Therapy Market

6. Global CAR-T Cell Therapy Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others)

6.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)

6.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

6.2.4. By Treatment Type (Single Treatment, Combination Treatment)

6.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)

6.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

6.2.7. By Region

6.2.8. By Company

6.3. Market Map

7. North America CAR-T Cell Therapy Market Outlook, 2016-2026F

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Product Type

7.2.2. By Tumor Type

7.2.3. By Indication

7.2.4. By Treatment Type

7.2.5. By Targeted Antigen

7.2.6. By End User

7.2.7. By Country

7.3. North America: Country Analysis

7.3.1. United States CAR-T Cell Therapy Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Product Type

7.3.1.2.2. By Tumor Type

7.3.1.2.3. By Indication

7.3.1.2.4. By Treatment Type

7.3.1.2.5. By Targeted Antigen

7.3.1.2.6. By End User

7.3.2. Canada CAR-T Cell Therapy Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Product Type

7.3.2.2.2. By Tumor Type

7.3.2.2.3. By Indication

7.3.2.2.4. By Treatment Type

7.3.2.2.5. By Targeted Antigen

7.3.2.2.6. By End User

7.3.3. Mexico CAR-T Cell Therapy Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Product Type

7.3.3.2.2. By Tumor Type

7.3.3.2.3. By Indication

7.3.3.2.4. By Treatment Type

7.3.3.2.5. By Targeted Antigen

7.3.3.2.6. By End User

8. Europe CAR-T Cell Therapy Market Outlook, 2016-2026F

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Product Type

8.2.2. By Tumor Type

8.2.3. By Indication

8.2.4. By Treatment Type

8.2.5. By Targeted Antigen

8.2.6. By End User

8.2.7. By Country

8.3. Europe: Country Analysis

8.3.1. Germany CAR-T Cell Therapy Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Product Type

8.3.1.2.2. By Tumor Type

8.3.1.2.3. By Indication

8.3.1.2.4. By Treatment Type

8.3.1.2.5. By Targeted Antigen

8.3.1.2.6. By End User

8.3.2. France CAR-T Cell Therapy Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Product Type

8.3.2.2.2. By Tumor Type

8.3.2.2.3. By Indication

8.3.2.2.4. By Treatment Type

8.3.2.2.5. By Targeted Antigen

8.3.2.2.6. By End User

8.3.3. Switzerland CAR-T Cell Therapy Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Product Type

8.3.3.2.2. By Tumor Type

8.3.3.2.3. By Indication

8.3.3.2.4. By Treatment Type

8.3.3.2.5. By Targeted Antigen

8.3.3.2.6. By End User

8.3.4. United Kingdom CAR-T Cell Therapy Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Product Type

8.3.4.2.2. By Tumor Type

8.3.4.2.3. By Indication

8.3.4.2.4. By Treatment Type

8.3.4.2.5. By Targeted Antigen

8.3.4.2.6. By End User

8.3.5. Italy CAR-T Cell Therapy Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Product Type

8.3.5.2.2. By Tumor Type

8.3.5.2.3. By Indication

8.3.5.2.4. By Treatment Type

8.3.5.2.5. By Targeted Antigen

8.3.5.2.6. By End User

8.3.6. Spain CAR-T Cell Therapy Market Outlook

8.3.6.1. Market Size & Forecast

8.3.6.1.1. By Value

8.3.6.2. Market Share & Forecast

8.3.6.2.1. By Product Type

8.3.6.2.2. By Tumor Type

8.3.6.2.3. By Indication

8.3.6.2.4. By Treatment Type

8.3.6.2.5. By Targeted Antigen

8.3.6.2.6. By End User

9. Asia-Pacific CAR-T Cell Therapy Market Outlook, 2016-2026F

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Product Type

9.2.2. By Tumor Type

9.2.3. By Indication

9.2.4. By Treatment Type

9.2.5. By Targeted Antigen

9.2.6. By End User

9.2.7. By Country

9.3. Asia-Pacific: Country Analysis

9.3.1. China CAR-T Cell Therapy Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Product Type

9.3.1.2.2. By Tumor Type

9.3.1.2.3. By Indication

9.3.1.2.4. By Treatment Type

9.3.1.2.5. By Targeted Antigen

9.3.1.2.6. By End User

9.3.2. Japan CAR-T Cell Therapy Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Product Type

9.3.2.2.2. By Tumor Type

9.3.2.2.3. By Indication

9.3.2.2.4. By Treatment Type

9.3.2.2.5. By Targeted Antigen

9.3.2.2.6. By End User

9.3.3. India CAR-T Cell Therapy Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Product Type

9.3.3.2.2. By Tumor Type

9.3.3.2.3. By Indication

9.3.3.2.4. By Treatment Type

9.3.3.2.5. By Targeted Antigen

9.3.3.2.6. By End User

9.3.4. Australia Global CAR-T Cell Therapy Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Type

9.3.4.2.2. By Product Type

9.3.4.2.3. By Technology

9.3.4.2.4. By Duration

9.3.4.2.5. By Application

9.3.4.2.6. By End User

9.3.5. South Korea Global CAR-T Cell Therapy Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Type

9.3.5.2.2. By Product Type

9.3.5.2.3. By Technology

9.3.5.2.4. By Duration

9.3.5.2.5. By Application

9.3.5.2.6. By End User

10. South America CAR-T Cell Therapy Market Outlook, 2016-2026F

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Product Type

10.2.2. By Tumor Type

10.2.3. By Indication

10.2.4. By Treatment Type

10.2.5. By Targeted Antigen

10.2.6. By End User

10.2.7. By Country

10.3. South America: Country Analysis

10.3.1. Brazil CAR-T Cell Therapy Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Type

10.3.1.2.2. By Product Type

10.3.1.2.3. By Technology

10.3.1.2.4. By Duration

10.3.1.2.5. By Application

10.3.1.2.6. By End User

10.3.2. Argentina CAR-T Cell Therapy Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Type

10.3.2.2.2. By Product Type

10.3.2.2.3. By Technology

10.3.2.2.4. By Duration

10.3.2.2.5. By Application

10.3.2.2.6. By End User

10.3.3. Colombia CAR-T Cell Therapy Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Type

10.3.3.2.2. By Product Type

10.3.3.2.3. By Technology

10.3.3.2.4. By Duration

10.3.3.2.5. By Application

10.3.3.2.6. By End User

11. Middle East & Africa CAR-T Cell Therapy Market Outlook, 2016-2026F

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Product Type

11.2.2. By Tumor Type

11.2.3. By Indication

11.2.4. By Treatment Type

11.2.5. By Targeted Antigen

11.2.6. By End User

11.2.7. By Country

11.3. Middle East & Africa: Country Analysis

11.3.1. Israel CAR-T Cell Therapy Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Type

11.3.1.2.2. By Product Type

11.3.1.2.3. By Technology

11.3.1.2.4. By Duration

11.3.1.2.5. By Application

11.3.1.2.6. By End User

11.3.2. Saudi Arabia CAR-T Cell Therapy Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Type

11.3.2.2.2. By Product Type

11.3.2.2.3. By Technology

11.3.2.2.4. By Duration

11.3.2.2.5. By Application

11.3.2.2.6. By End User

11.3.3. UAE Global CAR-T Cell Therapy Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Type

11.3.3.2.2. By Product Type

11.3.3.2.3. By Technology

11.3.3.2.4. By Duration

11.3.3.2.5. By Application

11.3.3.2.6. By End User

11.3.4. South Africa CAR-T Cell Therapy Market Outlook

11.3.4.1. Market Size & Forecast

11.3.4.1.1. By Value

11.3.4.2. Market Share & Forecast

11.3.4.2.1. By Type

11.3.4.2.2. By Product Type

11.3.4.2.3. By Technology

11.3.4.2.4. By Duration

11.3.4.2.5. By Application

11.3.4.2.6. By End User

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

14.1. Competition Outlook

14.2. Company Profiles

14.2.1. Gilead Sciences, Inc

14.2.2. Novartis International AG

14.2.3. Bristol Myers Squibb Co.

14.2.4. AbbVie Inc.

14.2.5. Cellectis SA

14.2.6. Amgen Inc

14.2.7. Pfizer Inc.

14.2.8. Merck & Co. Inc.

14.2.9. Intellia Therapeutics Inc.

14.2.10. Poseida Therapeutics Inc

14.2.11. Johnson & Johnson

14.2.12. Allogene Therapeutics Inc

14.2.13. Autolus Therapeutics PLC

14.2.14. Humanigen, Inc.

14.2.15. Sangamo Therapeutics, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

Figures and Tables

Figure 1: Global CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 2: Global CAR-T Cell Therapy Market Share, By Product Type, By Value, 2017-2027F

Figure 3: Global CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 4: Global CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 5: Global CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 6: Global CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 7: Global CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 8: Global CAR-T Cell Therapy Market Share, By Region, By Value, 2017-2027F

Figure 9: Global CAR-T Cell Therapy Market Share, By Company, By Value, 2021

Figure 10: Global CAR-T Cell Therapy Market Map, By Product Type, Market Size (USD Million) & Growth Rate (%), 2021

Figure 11: Global CAR-T Cell Therapy Market Map, By Indication, Market Size (USD Million) & Growth Rate (%), 2021

Figure 12: Global CAR-T Cell Therapy Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021

Figure 13: North America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 14: North America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 15: North America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 16: North America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 17: North America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 18: North America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 19: North America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F

Figure 20: United States CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 21: United States CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 22: United States CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 23: United States CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 24: United States CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 25: United States CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 26: Canada CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 27: Canada CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 28: Canada CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 29: Canada CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 30: Canada CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 31: Canada CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 32: Mexico CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 33: Mexico CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 34: Mexico CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 35: Mexico CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 36: Mexico CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 37: Mexico CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 38: Europe CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 39: Europe CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 40: Europe CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 41: Europe CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 42: Europe CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 43: Europe CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 44: Europe CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F

Figure 45: Germany CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 46: Germany CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 47: Germany CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 48: Germany CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 49: Germany CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 50: Germany CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 51: France CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 52: France CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 53: France CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 54: France CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 55: France CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 56: France CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 57: Switzerland CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 58: Switzerland CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 59: Switzerland CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 60: Switzerland CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 61: Switzerland CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 62: Switzerland CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 63: United Kingdom CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 64: United Kingdom CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 65: United Kingdom CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 66: United Kingdom CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 67: United Kingdom CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 68: United Kingdom CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 69: Italy CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 70: Italy CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 71: Italy CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 72: Italy CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 73: Italy CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 74: Italy CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 75: Spain CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 76: Spain CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 77: Spain CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 78: Spain CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 79: Spain CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 80: Spain CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 81: Asia-Pacific CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 82: Asia-Pacific CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 83: Asia-Pacific CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 84: Asia-Pacific CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 85: Asia-Pacific CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 86: Asia-Pacific CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 87: Asia-Pacific CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F

Figure 88: China CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 89: China CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 90: China CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 91: China CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 92: China CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 93: China CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 94: Japan CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 95: Japan CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 96: Japan CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 97: Japan CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 98: Japan CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 99: Japan CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 100: India CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 101: India CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 102: India CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 103: India CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 104: India CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 105: India CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 106: Australia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 107: Australia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 108: Australia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 109: Australia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 110: Australia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 111: Australia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 112: South Korea CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 113: South Korea CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 114: South Korea CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 115: South Korea CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 116: South Korea CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 117: South Korea CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 118: South America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 119: South America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 120: South America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 121: South America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 122: South America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 123: South America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 124: South America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F

Figure 125: Brazil CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 126: Brazil CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 127: Brazil CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 128: Brazil CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 129: Brazil CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 130: Brazil CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 131: Argentina CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 132: Argentina CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 133: Argentina CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 134: Argentina CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 135: Argentina CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 136: Argentina CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 137: Colombia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 138: Colombia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 139: Colombia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 140: Colombia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 141: Colombia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 142: Colombia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 143: Middle East & Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 144: Middle East & Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 145: Middle East & Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 146: Middle East & Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 147: Middle East & Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 148: Middle East & Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 149: Middle East & Africa CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F

Figure 150: Israel CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 151: Israel CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 152: Israel CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 153: Israel CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 154: Israel CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 155: Israel CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 156: Saudi Arabia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 157: Saudi Arabia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 158: Saudi Arabia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 159: Saudi Arabia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 160: Saudi Arabia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 161: Saudi Arabia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 162: UAE CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 163: UAE CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 164: UAE CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 165: UAE CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 166: UAE CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 167: UAE CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 168: South Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 169: South Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 170: South Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 171: South Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 172: South Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 173: South Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

List of Tables:

Table 1: Global Cancer Statistics, 2020

Table 2: Total Number of New Cancer Cases and Deaths Reported Globally, By Type, 2020

Table 3: Details of FDA Approved CAR-T Cell Therapies (As of February 2022)

Table 4: North America Cancer Statistics, 2020

Table 5: Total Number of New Cancer Cases and Deaths Reported in North America, By Type, 2020

Table 6: Europe Cancer Statistics, 2020

Table 7: Total Number of New Cancer Cases and Deaths Reported in North America, By Type, 2020

Table 8: Asia-Pacific Cancer Statistics, 2020

Table 9: Total Number of New Cancer Cases and Deaths Reported in Asia Pacific, By Type, 2020

Table 10: South America Cancer Statistics, 2020

Table 11: Total Number of New Cancer Cases and Deaths Reported in South America, By Type, 2020

Table 12: Middle East & Africa Cancer Statistics, 2020

Table 13: Total Number of New Cancer Cases and Deaths Reported in Middle East, By Type, 2020

Frequently asked questions

What is the market size of United States CAR-T Cell Therapy Market?

The United States CAR-T Cell Therapy Market stood at USD784.31 Million in 2021 since all 5 FDA-approved commercial CAR-T cell therapies are available in the United States. Kymriah and Yescarta were the first CAR-T cell therapies approved in the United States in 2017 and 2018, respectively, for the treatment of relapsed/refractory B-cell malignancies. Ever since the United States CAR-T cell therapy industry has been flourishing.

What is the scenario of CAR-T Cell Therapy Market in Asia Pacific Region?

Asia Pacific CAR-T Cell Therapy Market is expected to register the highest growth of around 72.58% during the forecast period. This can be attributed to the extensive research & development activities, ongoing clinical trials, increasing investments, expansion of companies in the region especially in countries like China, South Korea, Australia, Singapore, among others.

What are the major factors hindering the growth of Global CAR-T Cell Therapy Market?

The major factors slowing down the growth of Global CAR-T cell therapy market include high cost of cellular therapies, large scale manufacturing requirements, dearth of skilled healthcare professionals, stringent regulatory policies, limitation of car-t cell therapies, and lack of awareness.

What are the major market trends in Global CAR-T Cell therapy market?

The major trends in Global CAR-T Cell therapy market include Cell Therapy Manufacturing: Inside the Cell Shuttle, Automating Cell Production to Scale Out Manufacturing, Developing Allogenic Products, Engineering Natural Killer Cells For CAR-T Cell Therapy, Launch of Next Generation Platforms to Support CAR-T Cell Therapy Pipeline, Shift from Centralized to Decentralized Manufacturing Model, and others.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

CAR-T Cell Therapy Market to Grow at a robust CAGR of 64.66% During the Forecast Period

Mar, 2022

Increasing prevalence of different types of Cancer is driving the growth in Global CAR-T Cell Therapy market in the forecast period, 2022-2027.

Buy Now